Restart Life Receives Aggregate Gross Proceeds of Approximately $590,000 from Warrant Exercises and Loan 
BioStem Technologies Enters Into a Share Exchange Agreement
The Company will Acquire Back 10% of Issued and Outstanding Shares of its Non-Wholly Owned Subsidiary and Manufacturing Division POMPANO BEACH, FLORIDA.,...
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
SAN DIEGO, Calif., and SUZHOU, China and SHANGHAI, China, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global...
Goodness Growth Holdings Announces Management Reorganization
– Josh Rosen promoted to role of Interim Chief Executive Officer – – Company Founder, Dr. Kyle Kingsley, to assume...
Health Catalyst to Announce Fourth Quarter and Full Year 2022 Operating Results and Host Conference Call on Tuesday, February 28, 2023
SALT LAKE CITY, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of...
FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay® in Alagille Syndrome
Bylvay (odevixibat) granted Priority Review by U.S. FDAASSERT study demonstrated efficacy of Bylvay in pruritus, bile acids and sleep with...
Israel-Based Clearmind Medicine to Present at The OurCrowd Global Investor Summit Sponsored by Greenberg Traurig Tel Aviv
Dr. Adi Zuloff-Shani PhD., Clearmind’s chief executive officer will discuss its Nasdaq IPO with David Huberman, Capital Markets Shareholder at...
Intelligent Bio Solutions Inc. Reports Fiscal 2023 Second Quarter Financial Results and Operational Highlights
- Second quarter total revenue and government support income increased over 100% year-over-year - - Government support income increased 52%...
OrthoPediatrics Corp. to Report Fourth Quarter and Full Year 2022 Financial Results on March 1, 2023
WARSAW, Ind., Feb. 14, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (NASDAQ: KIDS), a company focused exclusively...
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2023 and Provides Corporate Update
Pre-launch commercial activities underway as Company advances toward U.S. Food and Drug Administration (FDA) Prescription Drug User Fee Act (PDUFA)...
Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast
NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and...
Endomimetics™ Announces a Research Collaboration Agreement with BISCO, Inc., to Support Development of a Dental Application of Bionanomatrix™
Funding matches Alabama Research and Development Enhancement Fund (ARDEF) grant to Kyounga Cheon, D.M.D., M.S., Associate Professor at the School...
Morphic to Present at SVB Leerink Global Healthcare Conference
WALTHAM, Mass., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral...
Athenex Announces a Reverse Stock Split
BUFFALO, N.Y., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery,...
InspireMD Announces Hiring of Medical Device Commercial Veteran Shane Gleason as General Manager of North America and VP of Global Marketing
Seasoned veteran in vascular space adds significant expertise in U.S. commercial market readiness and global strategic marketingTEL AVIV, Israel, Feb....
Trevena Announces Publication of OLINVYK Respiratory Physiology Study In ANESTHESIOLOGY
OLINVYK demonstrated a reduced impact on respiratory depression compared to IV morphine, among elderly/overweight subjects Study consistent with prior results...
Royal Biologics Announces U.S. Commercial Launch of BIOINCYTE™ PRFM
BIOINCYTE™ is a Next-Generation Autologous Fibrin and Platelet SystemHACKENSACK, N.J., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Royal Biologics, a company...
Indaptus Therapeutics Names Robert Martell, M.D., Ph.D. to its Board of Directors
NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company...
Neurona Therapeutics Announces FDA Clearance of Expanded Inclusion Criteria for Phase I/II Clinical Trial of NRTX-1001 Regenerative Cell Therapy in Patients with Dominant Hemisphere Drug-Resistant Focal Epilepsy
NRTX-1001 administration is well-tolerated and shows seizure reduction of >90% in the first two patients at six- and three-months post-treatment,...
Cidara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
SAN DIEGO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed...
Radiopharm Theranostics Initiates Process for Nasdaq Listing
Proposed listing on NASDAQ with RADX ticker symbolForm 20-F registration filed with Securities and Exchange CommissionTrading expected to commence late...